Abeona Therapeutics(ABEO)

Focus: Abeona Therapeutics is a Cleveland-based public biotech focused on gene transfer therapies for rare genetic diseases, particularly Sanfilippo syndrome and epidermolysis bullosa, operating at mid-cap scale with 1,001–5,000 employees.

Profile data last refreshed 46m ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

1001-5000

Open Jobs

Should You Work at Abeona Therapeutics?

AI assessment

High-risk, high-reward opportunity best suited for scientists and clinical professionals willing to accept restructuring or acquisition risk in exchange for early exposure to transformative rare-disease therapies.

Why Work Here

Pursuing multiple Phase 3 candidates (EB-101, MSI-78) with near-term regulatory catalysts in high-unmet-need rare diseases.

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$6M

Pipeline & Clinical Trials

ABO-101

Mucopolysaccharidosis III-B

N/A

Clinical Trials (1)

NCT04655911A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

N/A

Help build intelligence for Abeona Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline spanning gene therapy (COL7A1, NAGLU, UX111) and cell therapy (LZRSE-Col7A1), offering exposure to cutting-edge modalities.

Public company with active investor relations engagement and 2027 IND goal for ABO-701, signaling forward momentum despite tight cash position.

Watch Out For

Severe cash burn: $63.7M net loss on only $6M revenue (FY 2025); cash position of $23M provides limited runway absent near-term approval or financing.
Minimal hiring activity: only 2 active job openings and zero publications suggest limited near-term headcount growth or research output; R&D intensity of 590% unsustainable long-term.

Generated by Claude from Abeona Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Prademagene Zamikeracel

Recessive Dystrophic Epidermolysis Bullosa

N/A

Clinical Trials (2)

NCT07717736Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds

Phase 4

NCT07700966A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

N/A

ABO-102

MPS IIIA

Phase 1/2

rAAV9.CMV.hNAGLU

Mucopolysaccharidosis Type 3 B

Phase 1/2

Clinical Trials (1)

NCT03315182Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB

Phase 1/2

Collagen VII (COL7A1 gene transfer)

Recessive Dystrophic Epidermolysis Bullosa

Phase 1/2

NAGLU gene transfer

Mucopolysaccharidosis Type III B

Phase 1/2

LZRSE-Col7A1 Engineered Autologous Epidermal Sheets

Epidermolysis Bullosa Dystrophica

Phase 1/2

Clinical Trials (1)

NCT01263379Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

Phase 1/2

econazole

Onychomycosis

Phase 2

Clinical Trials (1)

NCT00385502A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail

Phase 2

UX111

MPS IIIA

Phase 2/3

EB-101

Recessive Dystrophic Epidermolysis Bullosa

Phase 3

Clinical Trials (3)

NCT04227106Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Phase 3

NCT05725018A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Phase 3

NCT05708677A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

N/A

MSI-78

Diabetic Foot Ulcers

Phase 3

Clinical Trials (2)

NCT00563394MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Phase 3

NCT00563433MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Phase 3

Interview Prep Quick Facts

Portfolio: 11 clinical trials

SEC Filings: 2 available

Open Roles: 2 active jobs

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

$6M66%

R&D Spend

$34M(590%)11%

Net Income

-$64M

Cash

$23M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Abeona Therapeutics(ABEO)

Should You Work at Abeona Therapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Abeona Therapeutics(10)

Open Jobs (2)

Nursery Senior /Senior Early Years Educator

Animal Carer

Financials (FY2025)

Hiring Trend